Skip to main content

Table 1 Summary of the studies showing an effect of blood pressure variability on the development of complications in patients with diabetes

From: Variability of risk factors and diabetes complications

Risk factor

Type of variability assessed

Short or long term variability

Metrics used

Type of study

Sample size

Significantly associated outcomes

Follow-up length

References

Systolic blood pressure

Visit-to-visit

Long-term

Standard deviation

Post-hoc analysis of trial

9114

MACE; microvascular outomes

2.4 years

[10]

Post-hoc analysis of trial

9114

MACE, renal events, or death;

7.6 years

[11]

Retrospective cohort study

124105

Newly developed CVD; all-cause mortality

39.5 months

[12]

Retrospective cohort study

10163

Risk of CVD

24 months

[13]

Prospective cohort study

632

MACE

11.3 years

[14]

Post-hoc analysis of 2 trials

2739

Composite renal outcome

2.6/3.4 years

[16]

Retrospective cohort study

30851

Composite renal outcome

4 years

[17]

Coefficient of variation

Post-hoc analysis of 2 trials

9383 plus 1550

Heart failure development

56.6 months/59.5 months

[15]

Retrospective cohort study

10163

Risk of CVD

24 months

[13]

Retrospective cohort study

30851

Composite renal outcome

4 years

[17]

Variation independent of mean

Retrospective cohort study

10163

Risk of CVD

24 months

[13]

Average real variability

Retrospective cohort study

10163

risk of CVD

24 months

[13]

Post-hoc analysis of 2 trials

9383 plus 1550

Heart failure related event

56.6 months/59.5 months

[15]

Retrospective cohort study

30851

Composite renal outcome

4 years

[17]

Successive variability of measurements

Retrospective cohort study

10163

Risk of CVD

24 months

[13]

Diastolic blood pressure

Visit-to-visit

Long-term

Coefficient of variation AND Average real variability

Post-hoc analysis of 2 trials

9383 plus 1550

Heart failure development

56.6 months/59.5 months

[15]